Biocardia, Inc. (BCDA) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on August 11, 2025, by Biocardia, Inc., a Delaware corporation. The filing serves to announce the company's financial results for the quarter ended June 30, 2025. The company's common stock and warrants trade on The Nasdaq Capital Market under the symbols BCDA and BCDAW, respectively.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a notification that a press release containing these details has been issued. The actual financial data is located in Exhibit 99.1 (the press release), which is referenced but not included in the text provided.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2025, by reviewing Exhibit 99.1 (the press release).
- Confirm the company's cash position and burn rate as detailed in the full financial statements referenced in the press release.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are critical for this biotechnology firm.
- Check for any new debt covenants or liquidity events mentioned in the full press release text.